Adenosine inhibits growth of human aortic smooth muscle cells via A2B receptors

被引:88
作者
Dubey, RK
Gillespie, DG
Mi, ZC
Jackson, EK
机构
[1] Univ Pittsburgh, Med Ctr, Dept Med, Ctr Clin Pharmacol, Pittsburgh, PA 15213 USA
[2] Univ Pittsburgh, Med Ctr, Dept Pharmacol, Pittsburgh, PA 15213 USA
关键词
adenosine; smooth muscle cells; hypertension; atherosclerosis; restenosis; proliferation; hyperplasia; extracellular matrix; collagen;
D O I
10.1161/01.HYP.31.1.516
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Adenosine inhibits rat vascular smooth muscle cell (SMC) growth. However, the effects of adenosine on human vascular SMC proliferation and synthesis of extracellular matrix proteins, such as collagen, are unknown. The objective of this study was to characterize the effects of exogenous and endogenous (SMC-derived) adenosine on human aortic SMC proliferation and collagen synthesis. Growth-arrested SMCs were stimulated with 2.5% fetal calf serum (FCS) in the presence and absence of adenosine, 2-chloroadenosine (stable adenosine analogue), and with agents that increase endogenous adenosine levels, including erythro-9-(2-hydroxy-3-nonyl) adenine (EHNA), dipyridamole, and iodotubericidin. All of these agents inhibited in a concentration-dependent manner FCS-induced SMC proliferation as assessed by DNA synthesis (H-3-thymidine incorporation) and cell counting, as well as collagen synthesis (H-3-proline incorporation). EHNA, dipyridamole, and iodotubericidin increased extracellular levels of adenosine by 1.7-fold to 18-fold when added separately to SMCs, and EHNA+iodotubericidin and EHNA+iodotubericidin+dipyridamole increased extracellular adenosine levels by more than 392-fold. Both KF17837 (selective A(2) antagonist) and DPSPX (A(1)/A(2) antagonist), but not DPCPX (selective A(1) antagonist), blocked the antimitogenic effects of 2-chloroadenosine, EHNA, and dipyridamole on DNA and collagen synthesis, suggesting the involvement of A(2A) and/or A(2B), but excluding the participation of A(1), receptors. The lack of effect of CGS21680 (selective A(2A) agonist), excluded involvement of A(2A) receptors and suggested a major role for A(2B) receptors. A comparison of the inhibitory potencies of 2-chloroadenosine, N-6-cyclopentyladenosine (selective A(1) agonist), NECA (A(1)/A(2) agonist), and MECA (A(1)/A(2) agonist) were consistent with an A(2B) receptor subtype mediating the inhibitory effects of adenosine on human aortic SMC proliferation. In conclusion, human aortic SMCs synthesize adenosine, and exogenous as well as endogenous (SMC-derived) adenosine inhibits SMC proliferation and collagen synthesis via activation of A(2B) receptors.
引用
收藏
页码:516 / 521
页数:6
相关论文
共 15 条
  • [1] DALZIEL HH, 1994, PHARMACOL REV, V46, P449
  • [2] Dubey Raghvendra K., 1996, Hypertension (Dallas), V28, P552
  • [3] Factors controlling growth and matrix production in vascular smooth muscle and glomerular mesangial cells
    Dubey, RK
    Jackson, EK
    Rupprecht, HD
    Sterzel, RB
    [J]. CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION, 1997, 6 (01) : 88 - 105
  • [4] Adenosine inhibits growth of rat aortic smooth muscle cells - Possible role of A(2b) receptor
    Dubey, RK
    Gillespie, DG
    Osaka, K
    Suzuki, F
    Jackson, EK
    [J]. HYPERTENSION, 1996, 27 (03) : 786 - 793
  • [5] Smooth muscle cell-derived adenosine inhibits cell growth
    Dubey, RK
    Gillespie, DG
    Mi, ZC
    Suzuki, F
    Jackson, EK
    [J]. HYPERTENSION, 1996, 27 (03) : 766 - 773
  • [6] Cyclic AMP Adenosine pathway inhibits vascular smooth muscle cell growth
    Dubey, RK
    Mi, ZC
    Gillespie, DG
    Jackson, EK
    [J]. HYPERTENSION, 1996, 28 (05) : 765 - 771
  • [7] Exogenous and endogenous adenosine inhibits fetal calf serum-induced growth of rat cardiac fibroblasts - Role of A(2B) receptors
    Dubey, RK
    Gillespie, DG
    Mi, ZC
    Jackson, EK
    [J]. CIRCULATION, 1997, 96 (08) : 2656 - 2666
  • [8] FUNCTIONAL-CHARACTERIZATION OF 3 ADENOSINE RECEPTOR TYPES
    GURDEN, MF
    COATES, J
    ELLIS, F
    EVANS, B
    FOSTER, M
    HORNBY, E
    KENNEDY, I
    MARTIN, DP
    STRONG, P
    VARDEY, CJ
    WHEELDON, A
    [J]. BRITISH JOURNAL OF PHARMACOLOGY, 1993, 109 (03) : 693 - 698
  • [9] Jackson EK, 1996, J HYPERTENS, V14, P19
  • [10] LI JM, 1995, AM J PHYSIOL, V269, pE519